Retro Biosciences, backed by Sam Altman, is raising $1 billion to extend human lifespan – TechCrunch
Latest
AI
Amazon
Apps
Biotech & Health
Climate
Cloud Computing
Commerce
Crypto
Enterprise
EVs
Fintech
Fundraising
Gadgets
Gaming
Government & Policy
Hardware
Layoffs
Media & Entertainment
Meta
Microsoft
Privacy
Robotics
Security
Social
Space
Startups
TikTok
Transportation
Venture
Events
Startup Battlefield
StrictlyVC
Newsletters
Podcasts
Videos
Partner Content
TechCrunch Brand Studio
Crunchboard
Contact Us
Posted:OpenAI CEO Sam Altman is doubling down on Retro Biosciences, a biotech startup based in San Francisco that wants humans to live 10 years longer than what it calls a healthy human lifespan.Altman previously provided Retro Biosciences’ entire seed round of $180 million. Now, the startup is raising a $1 billion Series A that Altman is joining, the Financial Times reports.Retro Biosciences, which says it plans to launch trials for drugs targeting diseases like Alzheimer’s, recently trained a model with OpenAI to turn regular cells into stem cells.CEO Joe Betts-LaCroix told the FT he wants to move fast by discovering and developing a drug “in the 2020s.” The startup joins other major billionaire-backed longevity efforts, including Altos Labs, which launched with $3 billion in 2022 backed by Jeff Bezos, and Unity Biotechnology, supported by both Bezos and Peter Thiel.TopicsSubscribe for the industry’s biggest tech newsEvery weekday and Sunday, you can get the best of TechCrunch’s coverage.TechCrunch’s AI experts cover the latest news in the fast-moving field.Every Monday, gets you up to speed on the latest advances in aerospace.Startups are the core of TechCrunch, so get our best coverage delivered weekly.By submitting your email, you agree to our Terms and Privacy Notice.© 2024 Yahoo.
